ZA200904289B - Polymorphs of a Mglur5 receptor antagonist - Google Patents

Polymorphs of a Mglur5 receptor antagonist

Info

Publication number
ZA200904289B
ZA200904289B ZA200904289A ZA200904289A ZA200904289B ZA 200904289 B ZA200904289 B ZA 200904289B ZA 200904289 A ZA200904289 A ZA 200904289A ZA 200904289 A ZA200904289 A ZA 200904289A ZA 200904289 B ZA200904289 B ZA 200904289B
Authority
ZA
South Africa
Prior art keywords
polymorphs
receptor antagonist
mglur5 receptor
mglur5
antagonist
Prior art date
Application number
ZA200904289A
Other languages
English (en)
Inventor
Thomas P Cleary
Alexander Glomme
Olaf Grassmann
Shan-Ming Kuang
Roland Meier
Doreen Miller
Regina Moog
Franziska E Rohrer
Jason Yang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39186951&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200904289(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ZA200904289B publication Critical patent/ZA200904289B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
ZA200904289A 2006-12-21 2009-06-18 Polymorphs of a Mglur5 receptor antagonist ZA200904289B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87639806P 2006-12-21 2006-12-21

Publications (1)

Publication Number Publication Date
ZA200904289B true ZA200904289B (en) 2010-04-28

Family

ID=39186951

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200904289A ZA200904289B (en) 2006-12-21 2009-06-18 Polymorphs of a Mglur5 receptor antagonist

Country Status (33)

Country Link
US (2) US8063076B2 (sl)
EP (1) EP2125779B1 (sl)
JP (1) JP5405311B2 (sl)
KR (1) KR101148580B1 (sl)
CN (1) CN101568531B (sl)
AR (1) AR064654A1 (sl)
AU (1) AU2007336369B2 (sl)
BR (1) BRPI0720954A2 (sl)
CA (1) CA2673444C (sl)
CL (1) CL2007003695A1 (sl)
CO (1) CO6210731A2 (sl)
CY (1) CY1117810T1 (sl)
DK (1) DK2125779T3 (sl)
EC (1) ECSP099431A (sl)
ES (1) ES2577391T3 (sl)
HR (1) HRP20160950T1 (sl)
HU (1) HUE029324T2 (sl)
IL (1) IL199181A (sl)
MA (1) MA31008B1 (sl)
MX (1) MX2009006694A (sl)
MY (1) MY148217A (sl)
NO (1) NO342451B1 (sl)
NZ (1) NZ577440A (sl)
PE (1) PE20081484A1 (sl)
PL (1) PL2125779T3 (sl)
PT (1) PT2125779T (sl)
RS (1) RS54853B1 (sl)
RU (1) RU2460728C2 (sl)
SI (1) SI2125779T1 (sl)
TW (1) TWI347320B (sl)
UA (1) UA96970C2 (sl)
WO (1) WO2008074697A1 (sl)
ZA (1) ZA200904289B (sl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101568531B (zh) 2006-12-21 2013-11-13 弗·哈夫曼-拉罗切有限公司 Mglur5受体拮抗剂的多晶型物
US20120039999A1 (en) * 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
AU2012232711B2 (en) 2011-03-18 2016-04-28 Novartis Ag Combinations of alpha 7 nicotinic acetylcholine receptor activators and mGluR5 antagonists for use in dopamine induced dyskinesia in Parkinson's Disease
EP2837631A1 (en) * 2013-08-14 2015-02-18 Merck & Cie New stable salt of 5,10-methylene-(6R)-tetrahydrofolic acid
GB201317022D0 (en) * 2013-09-25 2013-11-06 Addex Pharmaceuticals Sa Polymorphs
SG11201605449YA (en) 2014-01-10 2016-08-30 Birdie Biopharmaceuticals Inc Compounds and compositions for immunotherapy
CN115252792A (zh) 2016-01-07 2022-11-01 博笛生物科技有限公司 用于治疗肿瘤的抗-egfr组合
CN108794467A (zh) 2017-04-27 2018-11-13 博笛生物科技有限公司 2-氨基-喹啉衍生物
CN116056701A (zh) * 2020-06-05 2023-05-02 诺埃玛制药公司 治疗结节硬化复合症的方法
JP2023540849A (ja) * 2020-07-30 2023-09-27 ノエマ ファーマ アクツィエンゲゼルシャフト 三叉神経痛の治療方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3303199A (en) * 1963-07-15 1967-02-07 Geigy Chem Corp Certain imidazolone derivatives and process for making same
US3341548A (en) * 1964-04-29 1967-09-12 Hoffmann La Roche Nitroimidazoles and their preparation
DE2035905A1 (de) 1970-07-20 1972-02-03 Chemische Fabrik Stockhausen & Cie.,4150Krefeld Imidazolverbindungen und deren Herstellungsverfahren
CA1174673A (en) 1981-02-27 1984-09-18 Walter Hunkeler Imidazodiazepines
US4508560A (en) * 1981-11-11 1985-04-02 Ciba Geigy Corporation Certain pyridylacetylene compounds, compositions containing same and herbicidal methods of use
US4711962A (en) * 1984-10-18 1987-12-08 Stauffer Chemical Company Process for selective preparation of ratios of isomers formed on N-substitution of asymmetric imidazoles
KR0163595B1 (ko) 1989-06-30 1998-12-01 미리암디, 메코너헤이 치환된 이미다졸
TW544448B (en) 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
HUP0004412A3 (en) 1997-08-14 2003-06-30 Hoffmann La Roche Use of heterocyclic vinylethers for the preparation of pharmaceutical compositions treating neurological disorders
JP4815083B2 (ja) 1999-08-31 2011-11-16 メルク・シャープ・エンド・ドーム・コーポレイション 複素環化合物およびそれの使用方法
JP5154728B2 (ja) 2000-07-24 2013-02-27 クレニツキー・ファーマシューティカルズ，インコーポレイテッド 神経栄養活性を有する置換５−アルキニルピリミジン
NZ525917A (en) 2000-12-04 2005-11-25 F Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists and their use in treating mGLuR5 receptor mediated disorders
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
AU2002360621B2 (en) * 2001-12-19 2007-01-25 Merck & Co., Inc. heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5
TWI292318B (en) * 2003-03-10 2008-01-11 Hoffmann La Roche Imidazol-4-yl-ethynyl-pyridine derivatives
UA80888C2 (en) * 2003-06-05 2007-11-12 Hoffmann La Roche Imidazole derivatives as glutmate receptor antagonists
US7091222B2 (en) 2003-07-03 2006-08-15 Hoffmann-La Roche Inc. Imidazole derivatives
US7452909B2 (en) 2003-09-04 2008-11-18 Hoffman-La Roche Inc. Imidazole derivatives
RS50603B (sr) * 2004-06-01 2010-05-07 F. Hoffmann-La Roche Ag. Piridin-4-il-etinil-imidazoli i pirazoli kao antagonisti mglu5 receptora
CN101568531B (zh) 2006-12-21 2013-11-13 弗·哈夫曼-拉罗切有限公司 Mglur5受体拮抗剂的多晶型物

Also Published As

Publication number Publication date
JP2010513378A (ja) 2010-04-30
SI2125779T1 (sl) 2016-07-29
US8063076B2 (en) 2011-11-22
NZ577440A (en) 2011-12-22
CA2673444C (en) 2015-01-20
TW200833679A (en) 2008-08-16
HUE029324T2 (en) 2017-02-28
JP5405311B2 (ja) 2014-02-05
AU2007336369A1 (en) 2008-06-26
BRPI0720954A2 (pt) 2014-03-18
HRP20160950T1 (hr) 2016-10-07
CA2673444A1 (en) 2008-06-26
MY148217A (en) 2013-03-29
US8329912B2 (en) 2012-12-11
TWI347320B (en) 2011-08-21
KR101148580B1 (ko) 2012-05-24
RU2009123135A (ru) 2011-01-27
AR064654A1 (es) 2009-04-15
MX2009006694A (es) 2009-06-30
ECSP099431A (es) 2009-07-31
RU2460728C2 (ru) 2012-09-10
WO2008074697A1 (en) 2008-06-26
RS54853B1 (sr) 2016-10-31
IL199181A (en) 2016-02-29
CL2007003695A1 (es) 2008-07-04
EP2125779B1 (en) 2016-04-27
CN101568531B (zh) 2013-11-13
UA96970C2 (en) 2011-12-26
PL2125779T3 (pl) 2016-11-30
NO342451B1 (no) 2018-05-22
CY1117810T1 (el) 2017-05-17
PE20081484A1 (es) 2008-10-18
AU2007336369B2 (en) 2013-01-17
EP2125779A1 (en) 2009-12-02
CN101568531A (zh) 2009-10-28
PT2125779T (pt) 2016-07-19
US20120035222A1 (en) 2012-02-09
DK2125779T3 (en) 2016-07-04
NO20092357L (no) 2009-07-15
CO6210731A2 (es) 2010-10-20
ES2577391T3 (es) 2016-07-14
US20080312288A1 (en) 2008-12-18
KR20090081026A (ko) 2009-07-27
MA31008B1 (fr) 2009-12-01

Similar Documents

Publication Publication Date Title
HRP20160950T1 (hr) Polimorfi antagonista mglur5 receptora
HK1245264A1 (zh) 多晶型
EP2034832A4 (en) IL-8 RECEPTOR ANTAGONIST
HRP20151108T1 (en) Nogo receptor antagonists
EP2427430A4 (en) 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS
HK1123683A1 (en) Il-8 receptor antagonists il-8
IL196587A0 (en) 2-phenyl-indoles as prostaglandin d2 receptor antagonists
ZA201006830B (en) Heterocyclic compounds as adenosine receptor antagonist
EP1935874A4 (en) ANTAGONIST OF THE RECEIVER OF S1P3
IL194700A0 (en) Il-8 receptor antagonists
EP2099300A4 (en) IL-8 RECEPTOR ANTAGONISTS
ZA200903271B (en) Solid dispersion of a neurokinin antagonist
EP2191830A4 (en) SOLID PREPARATION COMPRISING A NPYY5 RECEPTOR ANTAGONIST
IL195807A0 (en) Cgrp receptor antagonists
ZA200808766B (en) Nitrated heterocyclic compounds as endothelin receptor antagonist
HK1206363A1 (zh) μ-阿片受體肽的有益鹽
EP2153736A4 (en) NEW LEUKOTRIEN RECEPTOR ANTAGONIST
IL205949A0 (en) 3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists
EP2089019A4 (en) POLYMORPHS OF AN ANTAGONIST OF TACHYKININ HYDRO-ISO-INDOLIC RECEPTORS
EP2057144A4 (en) NEW POLYMORPHIC FROM RIMONABANT
GB0525029D0 (en) Receptor Antagonist
ZA200810564B (en) 2-phenyl-indoles as prostaglandin D2 receptor antagonists
ZA200903609B (en) Motilide polymorphs
GB0701632D0 (en) MET receptor antagonists
GB0608516D0 (en) Receptor